Abstract Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can be life-threatening if left untreated. Over the past three decades, ribavirin and interferon-α have remained the only avail-able medicines for treating hepatitis C sufferers. Given that this combination therapy is partially effective at best and is associated with severe side-effects, there is an unmet need for new molecular entities which inhibit HCV replication. By employing a combination of structure-based drug design together with high-throughput screening approaches, several pharmaceutical companies have been successful in identifying potentially useful compounds for treating HCV infections. This article provides an overview of some of th...
Hepatitis C virus (HCV) infects nearly 170 million people worldwide and causes chronic hepatitis, ci...
Pegylated interferon α (peginterferon α) plus ribavirin is the present mainstay of treatment for pat...
OBJECTIVE: Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of trea...
Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can be life-th...
We finally stand at the brink of novel, oral, direct-acting antivirals for the treatment of hepatiti...
Although pegylated interferon-α plus ribavirin has become the standard for treating chronic hepatiti...
Hepatitis C virus (HCV) infection is an important cause of chronic hepatitis, cirrhosis, hepatocellu...
Objectives: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and soc...
Introduction: About 150 million people worldwide are estimated to be chronically infected with the h...
Treatment of chronic hepatitis C is currently based on a combination of pegylated interferon-α and r...
OBJECTIVES: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and ...
Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic ...
Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus ...
Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the ...
Copyright © 2013 J. González-Moreno and A. Payeras-Cifre.This is an open access article distributed...
Hepatitis C virus (HCV) infects nearly 170 million people worldwide and causes chronic hepatitis, ci...
Pegylated interferon α (peginterferon α) plus ribavirin is the present mainstay of treatment for pat...
OBJECTIVE: Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of trea...
Hepatitis C virus (HCV) infections affect about 170 million individuals worldwide and can be life-th...
We finally stand at the brink of novel, oral, direct-acting antivirals for the treatment of hepatiti...
Although pegylated interferon-α plus ribavirin has become the standard for treating chronic hepatiti...
Hepatitis C virus (HCV) infection is an important cause of chronic hepatitis, cirrhosis, hepatocellu...
Objectives: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and soc...
Introduction: About 150 million people worldwide are estimated to be chronically infected with the h...
Treatment of chronic hepatitis C is currently based on a combination of pegylated interferon-α and r...
OBJECTIVES: Chronic hepatitis C virus (HCV) infection represents a leading worldwide medical and ...
Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic ...
Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus ...
Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz. the ...
Copyright © 2013 J. González-Moreno and A. Payeras-Cifre.This is an open access article distributed...
Hepatitis C virus (HCV) infects nearly 170 million people worldwide and causes chronic hepatitis, ci...
Pegylated interferon α (peginterferon α) plus ribavirin is the present mainstay of treatment for pat...
OBJECTIVE: Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of trea...